You are here: Industry Insights > gilead

News List

Gilead to donate 2.4M bottles of Truvada in push to limit HIV infections fiercepharma
May 13, 2019
With HIV rates in the U.S. holding steady, health officials are looking to drugmakers for help containing its spread.
Gilead's $3B Truvada will face generics a year early. Can Descovy still win over its patients? fiercepharma
May 12, 2019
For years, Gilead Sciences has said its antiviral drug Truvada, used to treat and prevent HIV infection, wouldn’t face generic competition until 2021. But Gilead recently—and quietly—moved its generic expectations up a year.
Gilead, Goldfinch Enter Kidney Collaboration contractpharma
May 10, 2019
Gilead Sciences and Goldfinch Bio have entered a collaboration to discover, develop and commercialize a pipeline of therapeutics for diabetic kidney disease (DKD) and certain orphan kidney diseases.
Gilead, Goldfinch to team up against kidney disease pharmatimes
May 09, 2019
Gilead and Goldfinch Bio have collaborated to discover, develop and commercialise a pipeline of innovative therapeutics for diabetic kidney disease (DKD) and certain orphan kidney diseases.
Gilead partners with Goldfinch Bio to develop drugs for diabetic kidney disease firstwordpharma
May 09, 2019
Gilead Sciences entered a collaboration with Goldfinch Bio to develop and commercialise a pipeline of therapeutics for diabetic kidney disease (DKD) and certain orphan kidney diseases ...
Gilead Announces Topline Data From Phase 3 STELLAR-3 Study of Selonsertib in Bridging Fibrosis (F3) Due to Nonalcoholic Steatohepatitis (NASH) drugs
May 09, 2019
Gilead Announces Topline Data From Phase 3 STELLAR-3 Study of Selonsertib in Bridging Fibrosis (F3) Due to Nonalcoholic Steatohepatitis (NASH).
Gilead’s selonsertib flunks another NASH phase 3 fiercebiotech
April 28, 2019
Gilead’s NASH candidate selonsertib has disappointed in yet another phase 3 trial. This time, two different doses of the drug did worse than placebo at reducing scarring in patients with bridging fibrosis—also called stage 3 fibrosis—from nonalcoholic ste
Galapagos and Gilead announce positive Phase III results for filgotinib pharmaceutical-technology
April 23, 2019
Galapagos and Gilead announce positive Phase III results for filgotinib.
Gilead and insitro team up to develop treatment for NASH pharmaceutical-technology
April 18, 2019
Gilead Sciences has partnered with insitro, a data-driven drug discovery startup, to leverage an artificial intelligence (AI)-based platform for the discovery and development of new drugs to treat nonalcoholic steatohepatitis (NASH).
Gilead's first big TV push for triple combo Biktarvy showcases HIV diversity fiercepharma
April 18, 2019
Gilead Sciences wanted to represent the wide range of people living with HIV in its first national TV campaign for Biktarvy.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 21 22 Next page